Patent ID: 8518639
Filing Date: 2013-08-27
Classification: C12Q

Abstract:
1. A process for detecting in a sample at least one HPV, which can be oncogenic for the mucosal epithelia, wherein said detection comprises the determination of whether at least one amplicon has been, or is, produced from said sample, or from nucleic acid material thereof, by amplification by means of amplification primers, whereby the production of at least one amplicon indicates that at least one HPV, which can be oncogenic for the mucosal epithelia, is present in said sample, wherein said amplification primers comprise at least two primers of 14-30 nucleotides, the sequences of which are suitable for use as primers in the amplification of at least one target template sequence, wherein said at least one target template sequence is at least one of the HPV16 fragments, which comprise the sequence of SEQ ID NO: 122 or the complementary sequence thereof or a fragment of said sequence of SEQ ID NO: 122 or complementary sequence, wherein said HPV16 fragments differ by at most 5 nucleotides in length from said sequence of SEQ ID NO: 122 or complementary sequence, wherein said at least two primers of 14-30 nucleotides anneal to the 5′ terminal end of said at least one target template sequence and to the 5′ terminal end of the sequence that is complementary to said at least one target template sequence; and wherein said amplification primers further comprise at least two primers of 14-30 nucleotides, the sequences of which are suitable for use as primers in the amplification of at least one target template sequence, wherein said at least one target template sequence is at least one of the following HPV18 fragments: the HPV18 fragments, which comprise the sequence of SEQ ID NO: 64 or the complementary sequence thereof or a fragment of said sequence of SEQ ID NO: 64 or complementary sequence, wherein said HPV18 fragments differ by at most 5 nucleotides in length from said sequence of SEQ ID NO: 64 or complementary sequence, the HPV18 fragments, which comprise the sequence of SEQ ID NO: 65 or the complementary sequence thereof or a fragment of said sequence of SEQ ID NO: 65 or complementary sequence, wherein said HPV18 fragments differ by at most 5 nucleotides in length from said sequence of SEQ ID NO: 65 or complementary sequence, the HPV18 fragments, which comprise the sequence of SEQ ID NO: 66 or the complementary sequence thereof or a fragment of said sequence of SEQ ID NO: 66 or complementary sequence, wherein said HPV18 fragments differ by at most 5 nucleotides in length from said sequence of SEQ ID NO: 66 or complementary sequence, and the HPV18 fragments, which comprise the sequence of SEQ ID NO: 67 or the complementary sequence thereof or a fragment of said sequence of SEQ ID NO: 67 or complementary sequence, wherein said HPV18 fragments differ by at most 5 nucleotides in length from said sequence of SEQ ID NO: 67 or complementary sequence, wherein said at least two primers of 14-30 nucleotides anneal to the 5′ terminal end of said at least one target template sequence and to the 5′ terminal end of the sequence that is complementary to said at least one target template sequence.